Komori
Kissei Pharmaceutical (4547) · InitiativeAdvanced

Systematic Development of Specialist Talent for Strategy Execution

First written in FY2017. 3 of 6 entries say "Advanced", first in FY2024. Latest entry: FY2026.

6entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017 – FY2019AdvancedFY2024 – FY20262017: 120172018: 120182019: 120192020: 020202021: 020212022: 020222023: 020232024: 120242025: 120252026: 12026
Same theme, other companies
Strengthening Strategic Execution Through Talent Development and Human Resources System ReformA theme 8 companies write about · 0 as a headwind · 9 as a tailwind

The whole theme swung hardest in 2025: 1 of 6 companies on the "Worse" side.

5 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「The Company aims to enable all employees to use data and IT in their work, with the goal of having all employees reach at least the “Core” level※, defined as a score of 50 or higher.」

    Regarding the development of talent to execute its strategy, the Company has disclosed a specific target and learning opportunities based on a 4-tier DX literacy framework, with all employees required to reach at least the Core level, or a score of 50 or higher.
  2. FY2025AdvancedAnnual report

    「Regarding talent development, the Company has positioned “Developing self-directed talent” as its main vision for talent development and is working to develop creative talent capable of realizing its management strategy. It is expanding training by organizational level to strengthen its management ranks and implementing measures to develop DX talent.」

    The Company has linked the development of self-directed talent to the realization of its management strategy and disclosed specific measures and results, including training by organizational level, DX talent development, e-learning, and reskilling.
  3. FY2024AdvancedAnnual report

    「Based on this approach, the Company has positioned “Developing self-directed talent” as its main vision and has established the following 3 policies for talent development.」

    The Company has clarified its policy of systematically developing specialist talent as “Developing self-directed talent” and translated it into 3 specific policies: education, next-generation talent development, and support for self-directed learning.
  4. FY2019RestatedAnnual report

    「The Company will systematically develop talent with advanced specialist capabilities who can execute strategy in response to changes in the business environment.」

    The Company has reaffirmed the systematic development of specialist talent responsible for strategy execution as an issue under “Co-Creation.”
  5. FY2018RestatedAnnual report

    「The Company will systematically develop talent with advanced specialist capabilities who can execute strategy in response to changes in the business environment.」

    The Company has reaffirmed the systematic development of specialist talent responsible for strategy execution as an issue to be addressed under “Co-Creation.”
  6. FY2017First statedAnnual report

    「The Company will systematically develop talent with advanced specialist capabilities who can execute strategy in response to changes in the business environment.」

    As an issue to be addressed under the new medium-term management plan, “Co-Creation,” the Company has identified the systematic development of specialist talent required to execute its strategy.
Moved together

"Enhancing and Strengthening a Product Portfolio with Distinctive Features and Competitive Advantages" moved the same way as this thread, in the same document, in 3 of its 6 moves.

333333★123456
  1. ★This thread
  2. 1Enhancing and Strengthening a Product Portfolio with Distinctive Features and Competitive Advantages3×
  3. 2Efficient Advancement of Clinical Trials for Development Programs and Early Approval3×
  4. 3Establishing a Competitive Advantage and Securing Sales in the Domestic Prescription Pharmaceutical Market3×
  5. 4Promoting overseas expansion and stabilizing the overseas earnings base3×
  6. 5Building an Efficient Production System and Ensuring a Stable Supply of High-Quality Pharmaceuticals3×
  7. 6Stable dividends and profit allocation in line with earnings3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Kissei Pharmaceutical's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Systematic Development of Specialist Talent for Strategy Execution | KISSEI PHARMACEUTICAL CO.,LTD. (4547) | Komori